Drug General Information (ID: DDIG8D1IUR)
Drug Name			Ustekinumab		Drug Info		Iobenguane (I-131)		Drug Info
Drug Type		Monoclonal antibody				Small molecule
Therapeutic Class		Interleukin Inhibitors				Therapeutic Radiopharmaceuticals

Mechanism of Ustekinumab-Iobenguane (I-131) Interaction (Severity Level: Moderate)
Additive immunosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Ustekinumab				Iobenguane (I-131)
Mechanism 1		Immunosuppressive effects				Immunosuppressive effects
Key Mechanism Factor 1
		Factor Name		Immunosuppressive effects
		Factor Description		Immunosuppression is when your immune system is not functioning as it should. The immune system is made up of cells, tissues and organs that help the body fight off infections. If the immune system is suppressed, an infection that your body was able to control may become serious or even fatal.
Mechanism Description		Additive immunosuppressive effects by the combination of Ustekinumab and Iobenguane (I-131)
Mechanism 2		Myelosuppressive effects				Myelosuppressive effects
Key Mechanism Factor 2
		Factor Name		Immunosuppressive effects
		Factor Description		Immunosuppression is when your immune system is not functioning as it should. The immune system is made up of cells, tissues and organs that help the body fight off infections. If the immune system is suppressed, an infection that your body was able to control may become serious or even fatal.
Mechanism Description		Additive immunosuppressive effects by the combination of Ustekinumab and Iobenguane (I-131)

Recommended Action
Management		Caution is advised if ustekinumab must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy.

References
1	Product Information. Stelara (ustekinumab). Centocor Inc, Malvern, PA.